Literature DB >> 31576311

Improving patient selection for adjuvant therapy in high-risk renal cell carcinoma.

Dylan M Buller1, Benjamin T Ristau2.   

Abstract

Entities:  

Year:  2019        PMID： 31576311      PMCID： PMC6685884          DOI： 10.21037/atm.2019.04.75

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  32 in total

1.  Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.

Authors:  Daniel J George; Jean-Francois Martini; Michael Staehler; Robert J Motzer; Ahmed Magheli; Frede Donskov; Bernard Escudier; Sherry Li; Michelle Casey; Olga Valota; Brigitte Laguerre; Allan J Pantuck; Hardev S Pandha; Anup Patel; Maria Lechuga; Alain Ravaud
Journal:  Clin Cancer Res       Date:  2018-11-06       Impact factor: 12.531

2.  Vascular endothelial growth factor expression is increased in renal cell carcinoma.

Authors:  D Nicol; S I Hii; M Walsh; B Teh; L Thompson; C Kennett; D Gotley
Journal:  J Urol       Date:  1997-04       Impact factor: 7.450

3.  Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

Authors:  Alain Ravaud; Robert J Motzer; Hardev S Pandha; Daniel J George; Allan J Pantuck; Anup Patel; Yen-Hwa Chang; Bernard Escudier; Frede Donskov; Ahmed Magheli; Giacomo Carteni; Brigitte Laguerre; Piotr Tomczak; Jan Breza; Paola Gerletti; Mariajose Lechuga; Xun Lin; Jean-Francois Martini; Krishnan Ramaswamy; Michelle Casey; Michael Staehler; Jean-Jacques Patard
Journal:  N Engl J Med       Date:  2016-10-09       Impact factor: 91.245

4.  Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.

Authors:  Juana Dornbusch; Martina Walter; Andrea Gottschalk; Alice Obaje; Kerstin Junker; Carsten-Henning Ohlmann; Matthias Meinhardt; Aristeidis Zacharis; Stefan Zastrow; Olaf Schoffer; Marc-Oliver Grimm; Stefanie J Klug; Manfred P Wirth; Susanne Fuessel
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-03       Impact factor: 4.553

5.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

6.  Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis.

Authors:  A Takahashi; H Sasaki; S J Kim; K Tobisu; T Kakizoe; T Tsukamoto; Y Kumamoto; T Sugimura; M Terada
Journal:  Cancer Res       Date:  1994-08-01       Impact factor: 12.701

7.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Authors:  Federica Di Nicolantonio; Miriam Martini; Francesca Molinari; Andrea Sartore-Bianchi; Sabrina Arena; Piercarlo Saletti; Sara De Dosso; Luca Mazzucchelli; Milo Frattini; Salvatore Siena; Alberto Bardelli
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

8.  Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.

Authors:  Karim Chamie; Nicholas M Donin; Pia Klöpfer; Paul Bevan; Barbara Fall; Olaf Wilhelm; Stephan Störkel; Jonathan Said; Michael Gambla; Robert E Hawkins; Gustavo Jankilevich; Anil Kapoor; Evgeny Kopyltsov; Michael Staehler; Kimmo Taari; Alberto J A Wainstein; Allan J Pantuck; Arie S Belldegrun
Journal:  JAMA Oncol       Date:  2017-07-01       Impact factor: 31.777

9.  Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.

Authors:  Aziz Zaanan; Qian Shi; Julien Taieb; Steven R Alberts; Jeffrey P Meyers; Thomas C Smyrk; Catherine Julie; Ayman Zawadi; Josep Tabernero; Enrico Mini; Richard M Goldberg; Gunnar Folprecht; Jean Luc Van Laethem; Karine Le Malicot; Daniel J Sargent; Pierre Laurent-Puig; Frank A Sinicrope
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777

10.  VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.

Authors:  M Scartozzi; M Bianconi; L Faloppi; C Loretelli; A Bittoni; M Del Prete; R Giampieri; E Maccaroni; S Nicoletti; L Burattini; D Minardi; G Muzzonigro; R Montironi; S Cascinu
Journal:  Br J Cancer       Date:  2012-11-29       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.